Ryan White HIV/AIDS Program - State Profiles U.S. Department of Health and Human Services: Health Resources and Services Administration Ryan White HIV/AIDS Program
Home

The United StatesRyan White HIV/AIDS Program AIDS Drug Assistance Program (ADAP)6


The United States icon

The following section provides demographic and medical information on all Ryan White HIV/AIDS Program AIDS Drug Assistance Program (ADAP) clients in The United States in 2012.

ADAP Number of Clients Served

The estimated number of clients served by ADAP in The United States in 2012 was 244,436. A total of 34,743 new clients were served.

Note: A new ADAP client is an individual who has applied to the state ADAP for the first time ever and meets that ADAP's financial, medical, and other eligibility criteria. A new client may not necessarily be receiving medications or insurance assistance. The client may be on the waiting list, or may not have requested ADAP services.

ADAP Clients in The United States in 2012 by Gender

Display data as table
Display data as table
ADAP Clients in The United States in 2012 by Gender
Gender Number Percent
Male 194,380 79.6
Female 49,050 20.1
Transgender* 815 < 1
Total 244,245

Note: Gender was not reported for 191 client(s) (< 1%).

*Very few people self-identify with this group. Transgender is an individual whose gender identity is not congruent with his or her biological gender, regardless of the status of surgical and hormonal gender reassignment processes. Sometimes the term is used as an umbrella term encompassing transsexuals, transvestites, cross-dressers, and others. The term transgender refers to a continuum of gender expressions, identities, and roles, which expand the current dominant cultural values of what it means to be male or female.

ADAP Clients in The United States in 2012 by Race/Ethnicity

Display data as table
Display data as table
ADAP Clients in The United States in 2012 by Race/Ethnicity
Race/Ethnicity Number Percent
White (not Hispanic) 92,095 38.4
Black or African-American (not Hispanic) 79,918 33.3
Hispanic 59,254 24.7
Asian (not Hispanic) 4,002 1.7
Native Hawaiian/Pacific Islander (not Hispanic) 534 < 1
American Indian/Alaska Native (not Hispanic) 1,071 < 1
Multiracial (not Hispanic) 2,939 1.2
Total 239,813

Note: Race/ethnicity was not reported for 4,623 client(s) (1.9%).

ADAP Clients in The United States in 2012 by Age

Display data as table
Display data as table
ADAP Clients in The United States in 2012 by Age
Age Number Percent
Under 2 35 < 1
2 - 12 175 < 1
13 - 24 9,225 3.8
25 - 44 99,388 40.7
45 - 64 125,399 51.3
65 and Above 10,211 4.2
Total 244,433

Note: Age was not reported for 3 client(s) (< 1%).

ADAP Expenditures in The United States in 2012 by Type

Display data as table
Display data as table
ADAP Expenditures in The United States in 2012 by Type
Expenditure Type Number Percentage of All Expenditures
Insurance Coverage $ 295,443,005 15.0
Dispensing and Administrative Costs $ 43,208,334 2.2
Pharmaceuticals $ 1,621,075,169 82.4

Note: The total Expenditures do not include the amount spent under the ADAP Flexibility Policy and thus the percents may not add up to 100%.

ADAP Most Frequently Prescribed Drug Class in The United States in 2012

Display data as table
Display data as table
ADAP Most Frequently Prescribed Drug Class in The United States in 2012
Drug Class Number of Aggregate Clients
Protease Inhibitors 485,915
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 394,592
Multi-Class Combination 195,228
Integrase Inhibitors 88,072
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 74,646
Entry Inhibitors 6,568
Fusion Inhibitors 615

Note: Since a client can receive prescriptions across classes within the reporting period, the number of clients is duplicated within and across drug classes.

ADAP Most Frequently Prescribed Drug in The United States in 2012

Display data as table
Display data as table
ADAP Most Frequently Prescribed Drug in The United States in 2012
Drug Number of Aggregate Clients
Truvada 233,767
Norvir 210,207
Atripla 195,226
Reyataz 118,438
Prezista 89,757
Isentress 88,072
Epzicom 57,038
Kaletra 40,668
Viread 30,092
Viramune 26,652

Note: Since a client can receive many prescriptions of the same drug within the reporting period, the number of clients is duplicated within and across medications.